Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy

Journal of Oral Pathology and Medicine

Volumn 34, Issue 2, 2005, Pages 93-99

  Takemura, Kanako ^a,c   Noguchi, Makoto ^a   Ogi, Kazuhiro ^a,b   Tokino, Takashi ^b   Kubota, Hiromi ^a   Miyazaki, Akihiro ^a   Kohama, Geniku ^a   Hiratsuka, Hiroyoshi ^a  

^a Sapporo Medical University   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

^c NONE   (Japan)

Author keywords

Apoptosis; Bax; Oral squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; FLUOROURACIL; PROTEIN BAX;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL COUNT; CELL CYCLE G1 PHASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MOUTH NEOPLASMS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 12444303176     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2004.00257.x     Document Type: Article

References (38)

1. Saini A, Gore ME, Adeistein DJ. Chemotherapy for head and neck cancer. In: Evans PHR, Montgomery PQ, Gullane PJ, eds. Principal and Practical of Head and Neck Oncology. London, UK: Martin Danitz, 2003; 79-98.
2. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57.
3. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: Its significance in cancer and cancer chemotherapy. Cancer 1994; 73: 2013-26.
4. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992; 11: 121-39.
5. Barry MA, Behneke CA, Eastman A, et al. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990; 40: 2353-62.
6. Sorenson CM, Barry MA, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990; 82: 749-55.
7. Ormerod MG, Orr RM, Peacock JH. The role of apoptosis in cell killing by cisplatin: a flow cytometric study. Br J Cancer 1994; 69: 93-100.
8. Evans DL, Dive C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res 1993; 53: 2133-39.
9. Lane DP. p53, guardian of the genome. Nature 1992; 358: 15-6.
10. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
11. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 1997; 3: 614-20.
12. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell 1995; 80: 293-99.
13. Miyashita T, Krajewski S, Krajewski R, et al. Tumor suppressor p53 is a regulator of bcl-2 and Bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-805.
14. Xie X, Clausen OPF, Angelis PD, et al. The prognostic value of spontaneous Apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer 1999; 86: 913-20.
15. Takemura T, Noguchi M, Kinjyou N, et al. The correlation between Bax expression and neoadjuvant chemotherapeutic effects in patients with advanced oral squamous cell carcinoma. J Jpn Stomatol Soc 2002; 51: 266-72 (in Japanese).
16. Jia LQ, Osada M, Ishioka C, et al. Screening the p53 status of human cell lines using a yeast function assay. Mol Carcinog 1997; 19: 243-53.
17. Inagaki T, Matsuwari S, Takahashi R, et al. Establishment of human oral-cancer cell lines (KOSC-2 and -3) carrying p53 and c-myc abnormalities by geneticin treatment. Int J Cancer 1994; 15: 301-8.
18. Iimura M, Nakamura T, Shinozaki S, et al. Bax is downregulated in inflamed colonic mucosa of ulcerative colitis. Gut 2000; 47: 228-35.
19. Erhardt K, Auer G, Fallenius A, et al. Prognostic significance of nuclear DNA analysis in histological sections in mammary carcinoma. Am J Clin Oncol 1986; 9: 117-25.
20. Lowits BB, Casciato DA. Principles of medical oncology and cancer biology. In: Casciato DA, Lowitz BB, eds. Manual of Clinical Oncology, 4th edn. Philadelphia: Lippincott Williams and Wilkins, 2000; 3-28.
21. Penault-Llorca F, Bouadballah R, Devilard E, et al. Analysis of BAX expression in human tissues using the anti-BAX, 4F11 monoclonal antibody on paraffin sections. Pathol Res Pract 1998; 194: 457-64.
22. Su JH, Deng G, Cotman CW. Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. J Neuropathol Exp Neurol 1997; 56: 86-93.
23. Chen Y, Kayano T, Takagi M. Dysregulated expression of bcl-2 and bax in oral carcinomas: evidence of post-transcriptional control. J Oral Pathol Med 2000; 29: 63-9.
24. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlation with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4285-300.
25. Kanata H, Yane K, Ota I, et al. CDDP induces p53-dependent apoptosis in tongue cancer cells. Int J Oncol 2000; 17: 513-7.
26. Yoneda K, Yamamoto T, and Osaki T. p53- and p21-independent apoptosis of squamous cells induced by 5-fluorouracil and radiation. Oral Oncol 1998; 34: 529-37.
27. Bissery MC, Nohynek G, Sanderick GJ, et al. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 1995; 6: 339-55.
28. Bissery MC. Preclinical pharmacology of docetaxel (Review). Eur J Cancer 1995; 31A(Suppl. 4): S1-S6.
29. Stobel T, Swanson L, Korsmeyer S, et al. Bax enhances paclitaxel-induced apoptosis though a p53-independent pathway. Proc Natl Acad Sci USA 1996; 93: 14094-9.
30. Takahashi M, Kigawa Y, Kinagawa H, et al. Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells. Eur J Cancer 2000; 36: 1863-8.
31. Kawakami K, Tsukuda M, Mizuno H, et al. Alteration of the Bcl-2/Bax status of head and neck cancer cell lines by chemotherapeutic agents. Anticancer Res 1999; 19 (5B): 3927-32.
32. Harima Y, Harima K, Shikata N, et al. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J Cancer Res Clin Oncol 1998; 124: 503-10.
33. Sakakura C, Sweeney EA, Shirahata T, et al. Overexpression of Bax sensitises breast cancer MCF-7 cells to cisplatin and etoposide. Surg Today 1997; 27: 676-9.
34. Xu ZW, Friess H, Buchler MW, et al. Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis is induced by chemotherapeutic agents. Cancer Chemother Pharmacol 2002; 49: 504-10.
35. Guo B, Cao S, Toth K, et al. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma. Clin Cancer Res 2000; 6: 718-24.
36. Posner MS, Glisson B, Frenette G, et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001; 19: 1096-104.
37. Gilsson BS, Murphy BA, Frenette G, et al. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002; 20: 1593-9.
38. Colevas AD, Norris CM, Tishler RB, et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol 2002; 25: 153-9.